相关实验视频
Updated: May 27, 2025

08:50
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
19.5K
释放低CpG传递体的潜力,用于优质的CAR-T细胞治疗
Jianyao Zeng1, Yan Sun1,2, Yuan Fang2
1School of Medicine, Shanghai University, Shanghai, China.
Frontiers in immunology
|February 21, 2025
概括
这项研究开发了一种低CpG的转体子,用于化学抗原受体 (CAR) T细胞治疗,增强抗瘤疗效和减少炎症. 新型LCG CAR-T细胞在临床前模型中显示出更好的安全性和有效性.
科学领域:
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
- 转子子技术 转子技术
背景情况:
- 非病毒化学抗原受体 (CAR) T细胞疗法在瘤免疫治疗中显示出前景.
- 在DNA载体中的CpG序列引发炎症反应 (TLR9) 和T细胞耗尽,限制CAR-T的有效性.
- 目前的非病毒性CAR-T制备方法在转基因表达和T细胞持久性方面面临挑战.
研究的目的:
- 为改进CAR-T细胞制备而设计低CpG含量的转子子.
- 为了评估用修改过的转体子制备的化学抗原受体T细胞 (LCG CAR-T) 的疗效和安全性.
- 评估降低CpG含量对体内炎症反应和抗瘤活性的影响.
主要方法:
- 修改传递器 (JL) 转子,以创建一个低CpG的变体.
- 在体外评估LCG CAR-T细胞细胞毒性.
- 在体内评估LCG CAR-T细胞的疗效和小鼠模型 (BALB/c和M-NSG) 中的炎症反应.
- 对炎症因素,细胞因子释放,T细胞群 (CD4+CAR-T) 和瘤透淋巴细胞 (TIL) 的分析.
主要成果:
- 与未经修改的CAR-T细胞相比,LCG CAR-T细胞在体外表现出增强的细胞毒性.
- 在体内研究显示,LCG CAR-T细胞显著抑制瘤生长.
- LCG CAR-T细胞增加了CD4+CAR-T细胞群和TILs,同时调节了促炎性细胞因子的释放.
- 在LCG CAR-T细胞中观察到in vivo的炎症反应减少.
结论:
- 低CpG的传递转子使得安全有效的CAR-T细胞的制备成为可能.
- LCG CAR-T细胞提供了改善的抗瘤疗效和减少系统性炎症.
- 这种非病毒方法为推进CAR-T细胞治疗提供了一个有前途的战略.
相关概念视频
The Eukaryotic Promoter Region
16.1K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
16.1K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Cis-regulatory Sequences
9.7K
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
9.7K
Cooperative Binding of Transcription Regulators
6.3K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome. Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
6.3K
DNA Packaging
101.9K
Overview
101.9K

